Table 1

Androgen receptors in androgen-independent PCa patients

Primary treatmentaResponse (mo)Flutamide withdrawal responseARPSA decline in response to bicalutamide
1LHRH15wtNone
2LHRH+F20NoneCodon 877 ACT(Thr)→GCT(Ala)86%b
4ORCH+F36Nonewt10%
5LHRH+F12Nonewt25%
6LHRH+F24NoneCodon 877 ACT(Thr)→GCT(Ala)30%
9LHRHc24wtNone
12LHRH+F2412 moCodon 877 ACT(Thr)→GCT(Ala)>99%d
13LHRH+F48NonewtNone
14LHRH+F20NoneCodon 877 ACT(Thr)→AGT(Ser)51%
Codon 877 ACT(Thr)→GCT(Ala)
16ORCHc12wtNone
19ORCH18No amplification
20LHRH+F2NonewtNone
22LHRH42No amplification
24ORCH12No amplification
41ORCHe17wt
42ORCH+F9NoneNo amplification
43DESf72No amplification
44ORCH14wt
45ORCHNAwt
46ORCHg19wt
47LHRHc20wt
48LHRH+F20Nonewt
49LHRH15wt
50LHRH24No amplification
51LHRH12Codon 890 GAC(Asp)→AAC(Asn)None
52LHRH18wtNone
53LHRH+F6NAhwt
54LHRH38wt
55LHRH+F32NACodon 877 ACT(Thr)→GCT(Ala)
57LHRH+F3NAwt
59LHRH+F13NAwt
60LHRH+F12NAwt
63LHRH+F33NAwt
  • a Treatments were LHRH agonist (LHRH), orchiectomy (ORCH), LHRH agonist plus flutamide (LHRH+F), or diethylstilbestrol (DES). wt, wild type.

  • b Reflects PSA decline after 4 months of therapy, at which time bicalutamide was discontinued because of a possible drug interaction.

  • c No response to subsequent flutamide treatment.

  • d PSA fell to undetectable during therapy.

  • e Fifteen-month response to subsequent flutamide; no flutamide withdrawal response.

  • f Thirty-month response to subsequent orchiectomy plus flutamide; positive flutamide withdrawal response.

  • g Twelve-month response to subsequent flutamide; no flutamide withdrawal response.

  • h Data on these patients’ responses were not available.